New Game Mode. 👀 We just added Rapid Review, a brand new game mode to Rounds. This game mode lets you compete with friends with 1 hint and 1 minute to get as many diagnoses right as you can.

Illness script · Hematology

Essential Thrombocythemia

Clonal myeloproliferative neoplasm with autonomous megakaryocyte proliferation causing sustained thrombocytosis (>450K/µL), risking thrombosis and hemorrhage.

This illness script for Essential Thrombocythemia covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.

Updated Nov 19, 2026All scripts

01

Predisposing factors

  • Bimodal: middle-aged/older adults (median ~60) AND young women (20s-30s)
  • Slight female predominance
  • JAK2 V617F mutation in ~55% of cases
  • CALR mutation in ~25%; MPL mutation in ~5%
  • No major environmental risk factors identified
  • Family history of MPN slightly increases risk

02

Presentation

  • Often asymptomatic; found incidentally on routine CBC
  • Erythromelalgia: burning pain + erythema of hands/feet — classic microvascular symptom
  • Arterial thrombosis predominates: stroke, TIA, MI, digital ischemia
  • Venous thrombosis: Budd-Chiari, portal/splenic vein thrombosis
  • Hemorrhage (epistaxis, GI bleed) at extreme thrombocytosis (>1,500K) due to acquired vWD
  • Mild splenomegaly; pruritus less prominent than in polycythemia vera

03

Pathophysiology

  • Clonal megakaryocyte proliferation → excess platelet production independent of thrombopoietin
  • JAK2 V617F → constitutive JAK-STAT pathway activation → unregulated hematopoiesis
  • CALR mutations activate MPL (thrombopoietin receptor) mimicking ligand binding
  • Very high counts (>1,500K/µL) → acquired von Willebrand disease → paradoxical bleeding

04

Diagnostics

  • CBC: sustained platelets >450,000/µL on two separate measurements
  • Bone marrow biopsy (gold standard): clustered large megakaryocytes, no significant fibrosis or dysplasia
  • JAK2 V617F first; if negative, test CALR then MPL
  • Must exclude reactive thrombocytosis: check iron stores, CRP, ESR, spleen status
  • BCR-ABL PCR/FISH to rule out CML; WHO criteria require exclusion of other MPNs

05

Management

  • Low-risk (age <60, no prior thrombosis): low-dose aspirin alone
  • High-risk (age ≥60 OR prior thrombosis): hydroxyurea + aspirin — first-line cytoreduction
  • Interferon-alpha preferred in pregnancy (hydroxyurea is teratogenic)
  • Anagrelide is second-line; avoid in cardiovascular disease (cardiac side effects)
  • Avoid aspirin if platelets >1,500K — bleeding risk from acquired vWD outweighs benefit

06

Clinical pivots

How to separate this script from the look-alikes that show up on exams and on the wards.

  • Reactive thrombocytosis

    Reactive thrombocytosis has an identifiable secondary cause (infection, iron deficiency, post-splenectomy), no driver mutation, and resolves with treatment.

  • Polycythemia vera

    PV has elevated hematocrit/RBC mass and near-universal JAK2 V617F; ET has isolated thrombocytosis with normal red cell mass.

  • Primary myelofibrosis

    Myelofibrosis shows leukoerythroblastic smear with teardrop cells and marked BM fibrosis on biopsy — absent in ET.

  • Chronic myelogenous leukemia

    CML is BCR-ABL1 positive with marked leukocytosis and basophilia; ET lacks BCR-ABL and has isolated thrombocytosis.

View full library

Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.